CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing innovative cancer therapies that target G-quadruplex DNA structures in tumors. By creating 'smart' compounds that activate only in hypoxic conditions, it aims to reduce side effects and enhance treatment efficacy through synergistic drug release.
Cancer is the second leading cause of death globally.
In spite of the great advances in cancer therapy over the past two decades, there is still a pressing need to develop new therapies with reduced side effects caused by conventional therapies.
Historically, many chemotherapeutic approaches to treat cancer, have targeted DNA.
But targeting genomic DNA has some disadvantages such as undesired side effects due to low selectivity of most chemotherapeutics (e.g. cisplatin and alkylating agents).
In…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
